COBALT advised shareholders of UAB Ilsanta on the sale of 100% of the company’s shares to UAB ILS holding, managed by Gediminas Žiemelis

COBALT represented the shareholders of UAB Ilsanta, a Lithuanian company installing and distributing medical devices and equipment, on the sale of 100% of the company’s shares to UAB ILS holding.ILS holding is part of Gediminas Žiemelis’ investment company ŽIA valda.

Ilsanta installs and distributes medical devices and equipment in the Baltic States and represents such well-known producers as Boston Scientific, 3M, Ansell, Swan Morton, Unomedical, and Trumphf.

Ilsanta will complement the portfolio of companies managed by the pharmacy holding Pharnasanta Group. The main shareholder of Pharnasanta Group, which together with related entities holds 57.5% of the shares, is AB ŽIA valda.

Besides UAB Ilsanta, the pharmacy holding Pharnasanta Group, established in the Netherlands in the late 2017, owns the pharmaceuticals manufacturer Nativita, producing generic pharmaceutical products; one more company NTV Logistic will engage in the distribution of pharmaceutical products and will supply logistics services.

“This transaction confirms prevailing trends in the market, when large companies consolidate their business by way of acquisition, and the number of companies managed by individual natural persons in the market is declining. There will soon appear more such deals, and acquisitions will remain an attractive way for business to more rapidly expand and enter new markets,” says Dr Irmantas Norkus, COBALT Managing Partner in Lithuania.

In this transaction, COBALT team represented the shareholders of UAB Ilsanta in negotiations on the sale of shares and other transaction documentation and advised on all other transaction-related matters. The team was comprised of COBALT Managing Partner Dr Irmantas Norkus and Associate Mantas Juška. The investment banking company FINJUSTUS advised UAB Ilsanta on financial matters of the transaction.